Healthpluser

Spread the love

<figure class="img_container" style="float:left;margin-right:10px;width:350px;;margin-bottom:5px;max-width:100%;"><img width="590" height="442" class="unveil" loading="eager" style="width:100%;max-height:100%" src="https://img.etb2bimg.com/files/cp/upload-1716881542-ethealthworld.webp" data-src="https://etimg.etb2bimg.com/photo/118159721.cms" captionrendered="1" alt=""><figcaption class="caption"></figcaption></figure>Bengaluru: <a id="21441101" type="General" weightage="100" keywordseo="Edwards-Lifesciences" source="keywords" meta.keywordsubtype="org" meta.entityname="Edwards Lifesciences" meta.hostid="266" meta.entityid="Edwards Lifesciences" class="news-keywords" href="/tag/edwards+lifesciences">Edwards Lifesciences</a> beat analysts’ estimate for <a id="23731809" type="General" weightage="20" keywordseo="fourth-quarter-profit" source="keywords" class="news-keywords" href="/tag/fourth-quarter+profit">fourth-quarter profit</a> on Tuesday, helped by strong demand for its <a id="21441103" type="General" weightage="20" keywordseo="artificial-heart-valves" source="keywords" class="news-keywords" href="/tag/artificial+heart+valves">artificial heart valves</a> and other medical devices. Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for <a id="20938019" type="General" weightage="20" keywordseo="surgical-procedures" source="keywords" class="news-keywords" href="/tag/surgical+procedures">surgical procedures</a>, especially from older adults. Last week, larger peer <a id="20412536" type="General" weightage="20" keywordseo="Boston-Scientific" source="keywords" meta.keywordsubtype="org" meta.entityname="Boston Scientific" meta.hostid="266" meta.entityid="Boston Scientific" class="news-keywords" href="/tag/boston+scientific">Boston Scientific</a> forecast its annual profit above Wall Street estimate, banking on steady demand for <a id="21417113" type="General" weightage="20" keywordseo="heart-devices" source="keywords" class="news-keywords" href="/tag/heart+devices">heart devices</a>. <!– PROMOSLOT_M –> Edwards bought heart device makers JenaValve Technology and Endotronix in deals valued at about $1.2 billion in July, as it looks to become a pure-play structural heart company. <!– PROMOSLOT –> The company’s lead product, transcatheter aortic valve replacement (TAVR) device, is used for minimally invasive heart surgeries. Sales from the TAVR unit rose nearly 6per cent to $1.04 billion in the quarter ended December 31, compared with analysts’ average estimate of $1.01 billion, according to LSEG data. <!– PROMOSLOT_M –> Edwards has also been facing stiff competition for its TAVR devices from Abbott, Boston Scientific and Medtronic . The company expects its first-quarter adjusted profit to be between 58 cents and 64 cents, compared with the estimate of 59 cents. On an adjusted basis, California-based Edwards earned 59 cents per share for the fourth quarter, beating the estimate of 55 cents. <!– PROMOSLOT_M –><!– PROMOSLOT –> Its revenue rose 9per cent over the year earlier to $1.39 billion. The company also reiterated its adjusted profit forecast for 2025 at $2.40 to $2.50 per share. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) </body>","next_sibling":[{"msid":118139657,"title":"J&J Launches TECNIS PureSee Intraocular Lens for Presbyopia in India","entity_type":"ARTICLE","link":"/news/medical-devices/jj-launches-tecnis-puresee-intraocular-lens-for-presbyopia-in-india/118139657","link_next_mobile":"/news/medical-devices/jj-launches-tecnis-puresee-intraocular-lens-for-presbyopia-in-india/118139657?next=1","category_name":null,"category_name_seo":"medical-devices"}],"related_content":[],"seoschemas":false,"social_share":{"fb":"/information/medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices/118159639?utm_source=fb&utm_medium={{DEVICE_TYPE}}","x":"/information/medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices/118159639?utm_source=twitter&utm_medium={{DEVICE_TYPE}}","whatsapp":"/information/medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices/118159639?utm_source=wapp&utm_medium={{DEVICE_TYPE}}","linkdin":"/information/medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices/118159639?utm_source=linkedin&utm_medium={{DEVICE_TYPE}}","telegram":"/information/medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices/118159639?utm_source=telegram&utm_medium={{DEVICE_TYPE}}","copy":"/information/medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices/118159639?utm_source=copy&utm_medium={{DEVICE_TYPE}}"},"cat_msid":44909127,"cat_sub_msid":false,"msid":118159639,"entity_type":"ARTICLE","title":"Edwards Lifesciences beats revenue estimate on power in coronary heart gadgets","synopsis":"Buyers stay bullish on medical machine makers, anticipating them to learn from still-high demand for surgical procedures, particularly from older adults.","titleseo":"medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices","standing":"ACTIVE","authors":[],"analytics":{"feedback":0,"views":102,"shares":0,"engagementtimems":423000},"Alttitle":{"minfo":""},"next_promo_stories":[{"id":"117674599","type":"next_article"}],"artag":"Reuters","artdate":"2025-02-12 06:47:43","lastupd":"2025-02-12 07:07:57","breadcrumbTags":["Edwards Lifesciences","heart devices","fourth-quarter profit","medical device market","Boston Scientific","artificial heart valves","surgical procedures"],"secinfo":{"seolocation":"medical-devices/edwards-lifesciences-beats-profit-estimate-on-strength-in-heart-devices"}}” data-type=”information” id=”news_dtl_118159639″ page-title=”Edwards Lifesciences beats revenue estimate on power in coronary heart gadgets”>

Buyers stay bullish on medical machine makers, anticipating them to learn from still-high demand for surgical procedures, particularly from older adults.

Reuters

Up to date On Feb 12, 2025 at 07:07 AM IST

Learn by: 100 Business Professionals

Learn by 100 Business Professionals

Bengaluru: Edwards Lifesciences beat analysts’ estimate for fourth-quarter profit on Tuesday, helped by sturdy demand for its artificial heart valves and different medical gadgets.

Buyers stay bullish on medical machine makers, anticipating them to learn from still-high demand for surgical procedures, particularly from older adults.

Final week, bigger peer Boston Scientific forecast its annual revenue above Wall Avenue estimate, banking on regular demand for heart devices.

Edwards purchased coronary heart machine makers JenaValve Know-how and Endotronix in offers valued at about $1.2 billion in July, because it seems to be to turn into a pure-play structural coronary heart firm.

The corporate’s lead product, transcatheter aortic valve substitute (TAVR) machine, is used for minimally invasive coronary heart surgical procedures.

Gross sales from the TAVR unit rose almost 6per cent to $1.04 billion within the quarter ended December 31, in contrast with analysts’ common estimate of $1.01 billion, based on LSEG knowledge.

Edwards has additionally been going through stiff competitors for its TAVR gadgets from Abbott, Boston Scientific and Medtronic .

The corporate expects its first-quarter adjusted revenue to be between 58 cents and 64 cents, in contrast with the estimate of 59 cents.

On an adjusted foundation, California-based Edwards earned 59 cents per share for the fourth quarter, beating the estimate of 55 cents.

Its income rose 9per cent over the yr earlier to $1.39 billion.

The corporate additionally reiterated its adjusted revenue forecast for 2025 at $2.40 to $2.50 per share. (Reporting by Christy Santhosh in Bengaluru; Modifying by Shilpi Majumdar)